Dizhe Pharmaceutical (688192.SH): Multiple research results on hematoma products were selected for the 68th American Society of Hematology (ASH) Annual Meeting

^{Zhitong Financial App News, Dizhe Pharmaceutical (688192.SH) announced that at the 68th American Society of Hematology (ASH) Annual Meeting to be held in New Orleans, USA from December 12 to 15, the company will announce the 8 latest clinical research results of the hematologic tumor pipeline, including 3 oral reports and 5 poster presentations, involving the company's three core products in the field of hematoma - the highly selective JAK1 inhibitor Gorizhe® (golixitinib), and the LYN/BTK dual-target inhibitor peritinib (} birelentinib) and the new-generation EZH1/2 dual-target small molecule inhibitor GW5282. Among them, Collegel ^® and biritinib received oral reports, and GW5282 clinical study data on relapsed/refractory non-Hodgkin lymphoma (r/r NHL) will also be published for the first time.

According to reports, Gao Ruizhe ^® is the world's first and currently the only highly selective JAK1 inhibitor approved for peripheral T-cell lymphoma (PTCL). The drug has observed encouraging initial curative effects in exploratory studies of multiple T-cell lymphoma subtypes and some hematologic immune diseases. ^{At this conference, a total of 5 of the latest clinical research advances in Gaorizhe® were selected.}